Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Medtronic

Medtronic's Portfolio Management Unlikely To Be A 'Magic Bullet,' Says Needham

Needham published a report that pointed to previous comments from Medtronic plc's (NYSE: MDT) management that indicate the potential for changes in the coming year, with a spinoff of a large business considered an option.

3 Wide-Moat Stocks That Look Cheap: Biogen, Medtronic, and Bristol-Myers Squibb

3 Wide-Moat Stocks That Look Cheap: Biogen, Medtronic, and Bristol-Myers Squibb

: Major stock indices appear heading for weekly gains with the Fed’s first interest rate hike digested easily by investors. However, the market is expected to remain under pressure in the near term. So, because wide-moat companies generally do well in these market conditions, we think cheap wide-moat stocks Bristol-Myers…

Medtronic's US Trial Of GI Genius Endoscopy Module Reduces Missed Colorectal Polyps By 50%

Medtronic's US Trial Of GI Genius Endoscopy Module Reduces Missed Colorectal Polyps By 50%

Medtronic plc (NYSE:MDT) announced final findings from a study that confirmed the effectiveness of the GI Genius intelligent endoscopy module. GI Genius uses AI to aid in detecting colorectal polyps during colonoscopy, potentially helping to prevent colorectal cancer (CRC). The study published in Gastroenterology found that the use of GI Genius in conjunction with…

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

FDA Approves Medtronic's Recharge-Free Sacral Nerve Stimulation Therapy For Bladder, Bowel Control

The FDA has approved Medtronic plc's (NYSE:

Medtronic's Q3 Profit In Line With Expectation Despite COVID-19 Impact On Procedure Volume

Medtronic Plc's (NYSE: MDT) Q3 FY22 sales of $7.76

Recap: Medtronic Q3 Earnings

Medtronic (NYSE:MDT) reported its Q3 earnings results on Tuesday, February 22, 2022 at 06:45 AM. Here's what investors need to know about the announcement.

Medtronic Scores Expanded FDA Nod For Cardiac Cryoablation Catheters In Pediatric Patients With Heart Rhythm Condition

inkl

Read news from The Economist, FT, and more,
with one subscription

Expert Ratings For Medtronic

Expert Ratings For Medtronic

Within the last quarter, Medtronic (NYSE:MDT) has observed the following analyst ratings:

What 20 Analyst Ratings Have To Say About Medtronic

What 20 Analyst Ratings Have To Say About Medtronic

Medtronic (NYSE:MDT) has observed the following analyst ratings within the last quarter:

Where Medtronic Stands With Analysts

Where Medtronic Stands With Analysts

Medtronic (NYSE:MDT) has observed the following analyst ratings within the last quarter:

Medtronic Issues Voluntary Recall For TurboHawk Plus Directional Atherectomy System

Medtronic Issues Voluntary Recall For TurboHawk Plus Directional Atherectomy System

Medtronic Plc (NYSE: MDT) has initiated a voluntary recall to customers related to the risk associated with tip damage caused by guidewire prolapse in its 6 French (6Fr) TurboHawk Plus Directional Atherectomy System.

Analyst Ratings For Medtronic

Analyst Ratings For Medtronic

Analysts have provided the following ratings for Medtronic (NYSE:MDT) within the last quarter:

10 Biggest Price Target Changes For Tuesday

10 Biggest Price Target Changes For Tuesday

Needham cut Medtronic plc (NYSE: MDT) price target from $131 to $128. Medtronic shares fell 0.7% to $103.44 in pre-market trading.

Medtronic Recalls HawkOne Atherectomy System Due To Tip Damage Risk

Medtronic Recalls HawkOne Atherectomy System Due To Tip Damage Risk

Medtronic Inc (NYSE: MDT) is recalling HawkOne Directional Atherectomy System due to the risk of the guidewire within the

Get all your
news in one place.

100’s of premium titles.
One news app.

Tribune News Service

FDA: Medtronic slow to update, recall defective insulin pumps for diabetes patients

While the U.S. Food and Drug Administration acknowledges Medtronic is actively working on fixing issues within its diabetes business, especially in regard to some of its insulin pumps, it says the steps took too long and are not enough.

Organisations

US Federal Reserve

Bristol-Myers Squibb

U.S. Food and Drug Administration

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play